[Form 4] Edesa Biotech, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Pardeep Nijhawan, Chief Executive Officer, Director and reported >10% owner of Edesa Biotech, Inc. (EDSA), received a grant of 5,908 restricted share units that vested in full upon grant on 10/02/2025 under the company's 2019 Equity Incentive Compensation Plan. The filing shows 475,644 common shares beneficially owned following the transaction, with 341,702 shares held indirectly by Pardeep Nijhawan Medicine Professional Corporation and additional indirect holdings through related entities and a family trust totaling 118,726 shares. The filing includes standard disclaimers that the reporting person disclaims beneficial ownership of certain indirect holdings except to the extent of pecuniary interest. The form was signed by an attorney-in-fact on 10/03/2025.

Positive

• 5,908 restricted share units vested in full, increasing the insider's stake and aligning CEO's economic interest with shareholders
• Total beneficial ownership reported at 475,644 shares, providing transparent disclosure of insider holdings

Negative

• None.

Insights

Corporate Governance Specialist

Insider received 5,908 vested RSUs; total holdings now 475,644 shares.

The filing documents a grant of restricted share units that vested immediately, which increases the reporting person's direct equity stake to 475,644 shares as of 10/02/2025. Immediate vesting removes future time-based alignment but does increase the insider's reported ownership level.

The report also notes multiple indirect holdings—341,702 shares via a professional corporation and other entities totaling 118,726—with standard disclaimers asserting pecuniary interest only. This clarifies the composition of the insider's economic exposure without changing any disclosed contractual terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM A6 L3R 5H6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/02/2025		A		5,908	A	$0(1)	475,644	D
Common Shares								341,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(2)
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(3)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160 Ontario Inc.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did EDSA insider Pardeep Nijhawan report on Form 4?

The Form 4 reports a grant of 5,908 restricted share units that vested in full on 10/02/2025.

How many shares does Pardeep Nijhawan beneficially own after the transaction?

The filing shows 475,644 common shares beneficially owned following the reported transaction.

Are any of the reported shares held indirectly for Pardeep Nijhawan?

Yes. 341,702 shares are held by Pardeep Nijhawan Medicine Professional Corporation and 118,726 shares are held by related entities and a family trust, per the Form 4.

What was the reported price for the RSU grant?

The restricted share units are reported with a price of $0, reflecting an award rather than a cash purchase.

When was the Form 4 signed and filed for this transaction?

The document shows signature by an attorney-in-fact on 10/03/2025 following the 10/02/2025 transaction date.